2019 Annual Report

On Course.

OUR PATHWAY TO OVERCOMING CANCER

Late-Stage, Diversified, Clinical Pipeline

Each of our four clinical-stage drug candidates target distinct mechanisms critical to overcoming cancer progression and drug resistance:

  • Pracinostat, an oral HDAC inhibitor;
  • ME-401, an oral PI3K delta inhibitor;
  • Voruciclib, an oral CDK inhibitor; and
  • ME-344, a mitochondrial inhibitor targeting the OXPHOS complex.
Read More >>

Shareholder Letter

This past year we’ve remained on course, executing a straightforward, purposeful strategy to advance our pipeline of four clinical-stage oncology candidates and build a strong foundation to deliver value to our stakeholders.

Read More >>

Leading with Industry Expertise

Our leadership team holds significant scientific, development and business expertise.

Read More >>